International Clinical Trial: A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444476) titled 'A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Biogen

Condition: Spinal Muscular Atrophy

Intervention: Drug: Salanersen

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: April 3, 2026

Target Sample Size: 90

To know...